Retatrutide + Cagrilintide Blend Research Compound (RC)

"Premium grade Retatrutide + Cagrilintide Blend validation."

The Retatrutide + Cagrilintide Blend is a pre-measured research blend pairing the triple GIP/GLP-1/glucagon receptor agonist retatrutide with the long-acting amylin analog cagrilintide, for multi-pathway metabolic research. Component pharmacology is documented for retatrutide (Rosenstock et al., Lancet 2023, PMID 37385280; Jastreboff et al., N Engl J Med 2023, PMID 37366315) and cagrilintide (Kruse et al., J Med Chem 2021, PMID 34288673). This blend research peptide is supplied lyophilized at ≥99% purity verified by HPLC, with identity confirmed by mass spectrometry and a batch-specific Certificate of Analysis (COA) included. Store lyophilized powder at −20 °C, protected from light and moisture. For laboratory research use only — not for human or animal consumption.